07 Jan 2001

Doxymono® 100 (Doxymono® 100/-200 Tabletten) - Deutschland

Updated: 07 Jan 2001

Doxymono® 100 | -200

Infektionen, verursacht durch Doxycyclin-empfindl. Krankheitserreger, z. B. d. Atemwege u. d. HNO-Bereiches, akute Schübe chron. Bronchitis, Sinusitis, Otitis media, Pneumonie durch Mykoplasmen, Rickettsien od. Chlamydien. Infekt. d. Urogenitaltraktes, Urethritis durch Chlamydien u. Ureaplasma urealyticum, akute Prostatitis, unkomplizierte Gonorrhoe (insb. b. gleichz. Chlamydieninf.). Infekt. d. weibl. Geschlechtsorgane, Syphilis b. Penicillin-Allergie, Harnwegsinfekt. (nur b. nachgewiesener Empf. d. Erregers). Infekt. d. Magen-Darm-Traktes, Cholera, Yersinien- od. Campylobacter-Infekt. Shigellen-Inf. b. Nachweis d. Empf. Malabsorptionssyndrome wie tropische Sprue u. Morbus Whipple. Ambulante Ther. v. Gallenwegsinfekt. Hauterkr. auch infizierte schwere Formen d. Akne vulg. u. Rosacea, Chlamydien-Konjunktivitis u. Trachom, Borreliosen wie Erythema chronicum migrans u. Lyme-Disease, seltene Infektionen, wie Bartonellose, Brucellose, Listeriose, Ornithose, Rickettsiose, Melioidose, Pest, Granuloma inguinale

Doxymono® 100 Description, Presentation and Dosage

Doxymono® 100 Description

Doxymono® 100 Drug Class Description


Doxymono® 100 Drug Description

1 teilbare Tbl. enth.: Doxycyclin 1H2O 104,1 mg/208,2 mg (entspr. 100 mg/200 mg Doxycyclin).

Doxymono® 100 Generic Name

Doxymono® 100/-200 Tabletten

Doxymono® 100 Presentation

Doxymono® 100 Presentation

Doxymono® 100/-200

Doxymono® 100 Manufacturer


Related Learning Zones

Anti-Infectives Knowledge Network CDI

Anti-Infectives Knowledge Network CDI

The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the therapy area of anti-infectives, with a particular focus on C. difficile infection.

Recent updates include ECCMID, ICDS, EBMT and ISICEM 2015 slide decks and congress reports, an infographic on ‘CDI in the EU’, data from the largest ever European clinician consensus report, as well as congress overviews, news reports and CDI expert perspectives.

Anti-Infectives Knowledge Network IFI

Anti-Infectives Knowledge Network IFI

The Anti-Infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, assembles the experience and expertise of a number of thought leaders in the area of anti-infectives, with a particular focus on invasive fungal infections.

This free resource is regularly updated with congress highlights, industry reports, policy changes, clinical guidelines and downloadable material from major medical events, so make sure you return often.

August 2015 MYC/15/0023/EUa

Doxymono® 100 Dosage

Doxymono® 100 Adult Dosage

mikrokristalline Cellulose, Magnesiumstearat, Poly(O-carboxymethyl)stärke-Natriumsalz, Povidon, hydriertes Rizinusöl, hochdisp. Siliciumdioxid.

Doxymono® 100 Precautions, Reactions and Contraindications

Doxymono® 100 Special Precautions

Doxymono® 100 Special Precautions

T 15 a, b

Doxymono® 100 Adverse Reactions

Doxymono® 100 Adverse Reactions

T 15

Related Drugs - Infectious Diseases

Back to top